Cingulate (CING) +200%. Nova Lifestyle (NVFY) +168%. SEALSQ (LAES) +90%. Enveric Biosciences (ENVB) +21% after initiating preclinical development of EB-003 in 2024 in preparation for IND submission. ...
Source LinkCingulate (CING) +200%. Nova Lifestyle (NVFY) +168%. SEALSQ (LAES) +90%. Enveric Biosciences (ENVB) +21% after initiating preclinical development of EB-003 in 2024 in preparation for IND submission. ...
Source Link
Comments